Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07934040 in Advanced Solid Tumors With KRAS Mutations
NCT06447662Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pf-07934040 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and 1 more, sponsored by Pfizer. Started Jun 2024; status: active, not recruiting.
02
Drugs
pf-07934040
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06447662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447662.